DDInter125 DDInter640
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Asenapine {u} (Compound) binds {v} (Gene) HRH2
HRH2 {u} (Gene) is bound by {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxepin
Doxepin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Asenapine {u} (Compound) binds {v} (Gene) HRH1
HRH1 {u} (Gene) is bound by {v} (Compound) Haloperidol
Haloperidol {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Trifluoperazine
Trifluoperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Asenapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Encorafenib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Encorafenib
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Asenapine (Compound) binds HRH2 (Gene) and HRH2 (Gene) is bound by Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Asenapine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Haloperidol (Compound) and Haloperidol may lead to a major life threatening interaction when taken with Encorafenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Asenapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib